Search Results - Pearce, Tillman E

  • Showing 1 - 6 results of 6
Refine Results
  1. 1
    Phase 1 dose-escalation study evaluating the safety, pharmacokinetics, and clinical activity of OBI-3424 in patients with advanced or metastatic solid tumors

    Phase 1 dose-escalation study evaluating the safety, pharmacokinetics, and clinical activity of OBI-3424 in patients with advanced or metastatic solid tumors by Tsimberidou, Apostolia Maria, Verschraegen, Claire F., Wesolowski, Robert, Shia, Chi-Sheng, Hsu, Pei, Pearce, Tillman E.

    Get full text
    Items that this one cites
    Article
    Save to List
    Saved in:
  2. 2
    Abstract OT-13-10: Global Phase 3 Study of Adagloxad Simolenin (OBI-822) and OBI-821 Versus Placebo Treatment for High Risk Early Stage Triple Negative Breast Cancer Patients (TNBC) Following Neoadjuvant or Adjuvant Chemotherapy

    Abstract OT-13-10: Global Phase 3 Study of Adagloxad Simolenin (OBI-822) and OBI-821 Versus Placebo Treatment for High Risk Early Stage Triple Negative Breast Cancer Patients (TNBC... by Rugo, Hope, Chow, Louis W.C., Cortes, Javier, Fasching, Peter A., He, Xu-Bing, Hsu, Pei, Huang, Chiun-Sheng, Kim, Sung-Bae, Lu, Yen-Shen, Melisko, Michelle, Nanda, Rita, Pearce, Tillman E, Sharma, Priyanka, Schwab, Richard

    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  3. 3
    Uniform detection of HIV-1 in alveolar macrophages of pediatric but not adult AIDS patients

    Uniform detection of HIV-1 in alveolar macrophages of pediatric but not adult AIDS patients by Pearce, Tillman E., Nowakowski, Maja, Eden, Edward, Huang, Zheng‐Bo, Steiner, Phillip, Shahabuddin, Muhammad, Potash, Mary Jane, Volsky, David J.

    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  4. 4
    Fontolizumab in moderate to severe Crohn's disease: A phase 2, randomized, double‐blind, placebo‐controlled, multiple‐dose study

    Fontolizumab in moderate to severe Crohn's disease: A phase 2, randomized, double‐blind, placebo‐controlled, multiple‐dose study by Reinisch, Walter, de Villiers, Williem, Bene, László, Simon, László, Rácz, István, Katz, Seymour, Altorjay, István, Feagan, Brian, Riff, Dennis, Bernstein, Charles N., Hommes, Daniel, Rutgeerts, Paul, Cortot, Antoine, Gaspari, Michael, Cheng, May, Pearce, Tillman, Sands, Bruce E.

    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  5. 5
    OBI-3424, a Novel AKR1C3-Activated Prodrug, Exhibits Potent Efficacy against Preclinical Models of T-ALL

    OBI-3424, a Novel AKR1C3-Activated Prodrug, Exhibits Potent Efficacy against Preclinical Models of T-ALL by Evans, Kathryn, Duan, JianXin, Pritchard, Tara, Jones, Connor D, McDermott, Lisa, Gu, Zhaohui, Toscan, Cara E, El-Zein, Narimanne, Mayoh, Chelsea, Erickson, Stephen W, Guo, Yuelong, Meng, Fanying, Jung, Donald, Rathi, Komal S, Roberts, Kathryn G, Mullighan, Charles G, Shia, Chi-Sheng, Pearce, Tillman, Teicher, Beverly A, Smith, Malcolm A, Lock, Richard B

    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  6. 6
    Phase I study of evofosfamide, an investigational hypoxia‐activated prodrug, in patients with advanced leukemia

    Phase I study of evofosfamide, an investigational hypoxia‐activated prodrug, in patients with advanced leukemia by Badar, Talha, Handisides, Damian R., Benito, Juliana M., Richie, Mary Ann, Borthakur, Gautam, Jabbour, Elias, Harutyunyan, Karine, Konoplev, Sergej, Faderl, Stefan, Kroll, Stew, Andreeff, Michael, Pearce, Tillman, Kantarjian, Hagop M., Cortes, Jorge E., Thomas, Deborah A., Konopleva, Marina

    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:

Search Tools: